Fujifilm Holdings Corp · TSE:4901
Fujifilm — Q2 FY2025 Earnings Presentation
37 slides from Fujifilm's earnings presentation, Nov 6, 2025
Slide 1: Earnings Presentation: Financial Results for Q2 FY2025
Earnings Presentation Financial Results for Q2 FY2025 November 6, 2025 FUJIFILM Holdings Corporation Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are m anage ment’s current assumptions and beliefs based on currently availa
Slide 2: Agenda
Agenda Consolidated Financial Results for Q2 FY2025 (July to September 2025) Earnings Highlights and Key Topics 1 Teiichi Goto, President, Representative Director & CEO FUJIFILM Holdings Corporation Financial Results and Business Summary by Operating Segment 2 Masayuki Higuchi, Director & Corporate
Slide 3: Earnings Highlights and Key Topics
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 Earnings Highlights and Key Topics 01 FUJIFILM Holdings Corporation 3
Slide 4: Consolidated Performance for Q2 FY2025
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Earnings Highlights for Q2 FY2025 Consolidated Performance for Q2 FY2025 (Exchange rates: ¥148/US$ | -¥1 YoY; ¥172/Euro | +¥8 YoY) Revenue Operating income Net income attributable to FUJIFILM Holdings Record high Record high Record high ¥ 822.
Slide 5: Full-year Forecast for FY2025
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Earnings Highlights for Q2 FY2025 Full-year Forecast for FY2025 (Exchange rates: Q3-4 ¥145/US$, ¥155/Euro, Full-year ¥145/US$, ¥162/Euro YoY) Revenue Operating income Net income attributable to FUJIFILM Holdings Record high Record high Record
Slide 6: Key Topics for Q2 FY2025: Medical Systems in Africa
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Key Topics for Q2 FY2025 Medical Systems With the dual aims of resolving local medical issues and expanding our business, we are collaborating with African governments and local partners to provide a broad range of solutions, all supported by
Slide 7: Key Topics for Q2 FY2025: Bio CDMO
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Key Topics for Q2 FY2025 Bio CDMO Opened a Bio CDMO site in North Carolina, which is one of the largest cell culture biomanufacturing sites in North America Construction for the second-phase investment (planned start of operation in FY2028) is
Slide 8: Key Topics for Q2 FY2025: Semiconductor Materials-1
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Key Topics for Q2 FY2025 Semiconductor materials-1 Fujifilm’s copper interconnect CMP slurry, boasting the world’s top share, is driving growth in the Semiconductor Materials business amid miniaturization and stacking of semiconductors ▍ Fujif
Slide 9: Key Topics for Q2 FY2025: Semiconductor Materials-2
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Key Topics for Q2 FY2025 Semiconductor materials-2 Launched CMP slurry for advanced packaging, which is an evolution of Fujifilm’s copper interconnect CMP slurry Aim for No. 1 global share of total CMP slurry market in FY2030 No growth ▍Target
Slide 10: Financial Results and Business Summary by Operating Segment
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 Financial Results and Business Summary by Operating Segment 02 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies with fi
Slide 11: Financial Results for Q2 FY2025
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Financial Results for Q2 FY2025 (Billions of yen) Q2 H1 FY2024 FY2025 Change Impact of Constant- FY2024 FY2025 Change Impact of Constant- exchange rate currency basis exchange rate currency basis Record high Record high Revenue 765.7 822.9 57.
Slide 12: Consolidated Revenue and Operating Income by Operating Segment
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 Consolidated Revenue and Operating Income by Operating Segment (Billions of yen) Q2 H1 Revenue FY2024 FY2025 Change FY2024 FY2025 Change Constant-currency basis Constant-currency basis * Healthcare 249.0 270.7 21.7 +8.7% 20.7 +8.3% 4
Slide 13: Business Summary: Healthcare
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 (July to September 2025) Business Summary: Healthcare Revenue and income （Billions of yen） Factors affecting revenue FY2024 FY2025 Change Constant- ◼ Medical Systems currency basis + Strong sales of endoscopes, medical IT, ultrasound
Slide 14: Business Summary: Electronics
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 (July to September 2025) Business Summary: Electronics Revenue and income （Billions of yen） Factors affecting revenue ◼ Semiconductor Materials FY2024 FY2025 Change Constant- currency basis + Strong sales of materials for advanced no
Slide 15: Business Summary: Business Innovation
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 (July to September 2025) Business Summary: Business Innovation Revenue and income （Billions of yen） Factors affecting revenue FY2024 FY2025 Change ◼ Business Solutions Constant- currency basis + Strong sales of DX solutions and servi
Slide 16: Business Summary: Imaging
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 (July to September 2025) Business Summary: Imaging Revenue and income （Billions of yen） Factors affecting revenue ◼ Consumer Imaging FY2024 FY2025 Change Constant- currency basis + Strong sales of instax instant photo systems ・Strong
Slide 17: Consolidated Cash Flow
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 (April to September 2025) Consolidated Cash Flow Cash in Cash out (Billions of yen) Adjusted free cash flow excluding business acquisitions FY2023 FY2024 FY2025 H1 H1 H1 (Billions of yen) Net income 112.7 110.8 120.5 4,000 Depreciati
Slide 18: Financial Forecast for FY2025
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Financial Forecast for FY2025 03 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100million. As a resul t, there may be some discrepancies from figures published in the past, and in some
Slide 19: Full-year Forecast for FY2025
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Full-year Forecast for FY2025 Revenue forecast is revised upward to reflect strong results, while operating income and net income attributable to FUJIFILM Holdings forecasts are unchanged (forecast as of August 6) (Billions of yen) FY2025 FY20
Slide 20: Financial Forecast by Operating Segment
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Financial Forecast by Operating Segment Operating income forecast is unchanged, as the downward revisions for both the Healthcare, mainly due to higher silver prices, and the Business Innovation, due to increased expenses for strengthening bus
Slide 21: Impact of the U.S. Tariff Policy
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Impact of the U.S. Tariff Policy Forecast impact of the U.S. tariff policy is unchanged from previous forecast Assumptions Based on information announced by the U.S. government as of November 1, Japan time. Reciprocal tariffs agreed upon or ap
Slide 22: Appendices: Financial Results for Q2 FY2025
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Appendices: Financial Results for Q2 FY2025 04 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100million. As a resul t, there may be some discrepancies from figures published in the pas
Slide 23: Q2 | H1 Earnings
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 | H1 Earnings (Billions of yen) Q2 H1 Revenue FY2025 FY2025 FY2024 Change Constant-currency basis FY2024 Change Constant-currency basis * Healthcare 249.0 270.7 21.7 +8.7% 20.7 +8.3% 484.2 499.2 14.9 +3.1% 24.4 +5.0% Medical Systems 166.9 1
Slide 24: Quarterly Earnings
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Quarterly Earnings (Billions of yen) FY2024 FY2025 Revenue Q1 Q2 Q3 Q4 Q1 Q2 * Healthcare 235.2 249.0 247.1 316.5 228.5 270.7 Medical Systems 157.7 166.9 162.6 206.1 144.0 170.3 Bio CDMO 47.1 48.1 51.3 73.0 53.2 66.3 LS Solutions 30.4 34.1 33.
Slide 25: Consolidated Revenue by Geographical Area
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Consolidated Revenue by Geographical Area (Billions of yen) FY2024 H1 FY2025 H1 Change Ratio (%) Ratio (%) Japan 33.3% 504.8 35.0% 550.0 45.2 +8.9% The Americas 20.4% 309.3 19.8% 310.6 1.3 +0.4% Europe 16.7% 253.6 17.4% 273.7 20.1 +7.9% China
Slide 26: Operating Income Analysis (Q2 YoY)
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Operating Income Analysis (Q2 YoY) (Billions of yen) Q2 （b-a) (a) (b) FY2024 FY2025 Operation Raw Material Tariff Change FX FY2024 FY2025 Business Detail Actual Actual and others price Impact One-time cost Q2 Q2 * Healthcare 19.5 19.4 (0.1) (0
Slide 27: Full-year Forecast for FY2025 Revenue by Business
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Full-year Forecast for FY2025 Revenue by Business (Billions of yen) FY2024 FY2025 FY2025 Change from Change from Actual Previous forecast Revised forecast previous year previous forecast (as of Aug. 6, 2025) (as of Nov. 6, 2025) * Healthcare 1
Slide 28: Operating Income Analysis (FY2025 Forecast vs. Previous Forecast)
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Operating Income Analysis (FY2025 Forecast vs. Previous Forecast) (Billions of yen) Previous Revised (a) (b) forecast forecast Operation Raw Material （b-a) Change FX tariff Previous Revised Business Detail (Aug 6,2025) (Nov.6,2025) and others
Slide 29: Bio CDMO Profitability
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Bio CDMO Profitability (Q2 YoY; FY2025 Forecast vs. Previous Year Results) EBITDA margin, excluding one-time costs, was in the low-teens percentage range for the second quarter, and is forecast to be mid-teens% for the full year, consistent wi
Slide 30: Consolidated Balance Sheets
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Q2 FY2025 Consolidated Balance Sheets (Billions of yen) Change from Change from Mar. 2024 Mar. 2025 Sep. 2025 Mar. 2024 Mar. 2025 Sep. 2025 Mar. 2025 Mar. 2025 Cash and cash equivalents 179.7 172.1 160.9 (11.2) Short-term and long-term debt 50
Slide 31: Capital Expenditure and Depreciation & Amortization
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Capital Expenditure and Depreciation & Amortization Bio CDMO capital expenditure forecast has increased by 25.0 billion yen since previous forecast (Billions of due to higher labor and material costs yen) (Billions of yen) Capital Expenditure
Slide 32: R&D Expenses and SG&A Expenses
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices R&D Expenses and SG&A Expenses R&D Expenses and SG&A Expenses Ratio to revenue (Billions of yen) (Ratio to revenue) 9,000 40.0% 900.0 (Billions of yen) 806.5 752.5 Q2 H1 Full Year FY2025 30.0% FY2024 FY2025 FY2024 FY2025 FY2024 Forecast 600.0
Slide 33: Market Trend and Number of Employees
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices Market Trend and Number of Employees ▐ Exchange rates (average) / Raw material prices (average) FY2024 FY2025 Unit Q1 Q2 Q3 Q4 Full Year Q1 Q2 H1 H2 Full Year US$ ¥/€ 156 149 152 152 152 145 148 146 145 145 € ¥/€ 168 164 163 161 164 164 172 16
Slide 34: References
Earnings Highlights Q2 FY2025 FY2025 Forecast Appendices References ▍ FUJIFILM Holdings - Investor Relations https://ir.fujifilm.com/en/investors.html ▍ FUJIFILM Holdings Integrated Report https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html ▍ IR Materials https://ir.fujifilm.com
Slide 35: Publication of Integrated Report 2025
Publication of Integrated Report 2025 The Report details our value creation story in reference to our transformation capability, highlighting how we are putting our Group purpose, “Giving our world more smiles,” into practice and generating innovation Main contents ⚫ Vision and Drivers for Enhancing
Slide 36: FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation
Slide 37: FUJIFILM Value from Innovation
FUJIFILM Value from Innovation